MAGAZINE

Ophthalmology Retina

Synchronous Diagnosis of Diabetic Retinopathy by a Handheld Retinal Camera, Artificial Intelligence, and Simultaneous Specialist Confirmation

AUTHORS & DATE

Gustavo Barreto Melo, MD, PhD, Luis Filipe Nakayama, MD, PhD, Viviane Santos Cardoso, MD, Lucas Andrade dos Santos, MS, Fernando Korn Malerbi, MD, PhD
14/11/2024

Abstract

Background

Diabetic retinopathy (DR) is a leading cause of preventable blindness, particularly in underserved regions where access to ophthalmic care is limited. This study presents a proof of concept for utilizing a portable handheld retinal camera with an embedded artificial intelligence (AI) platform, complemented by a synchronous remote confirmation by retina specialists, for DR screening in an underserved rural area.

Methods

A retrospective analysis of a screening initiative conducted in 4 municipalities in Northeastern Brazil, targeting the diabetic population. A portable handheld retinal camera captured macula-centered and disc-centered images, which were analyzed by the AI system. Immediate push notifications were sent out to retina specialists upon the detection of significant abnormalities, enabling synchronous verification and confirmation, with on-site patient feedback within minutes. Referral criteria were established, and all referred patients underwent a complete ophthalmic work-up and subsequent treatment.

Results

Out of 2052 invited individuals, 1115 participated, with a mean age of 60.93 years and diabetes duration of 7.52 years; 66.03% were women. The screening covered 2222 eyes, revealing various retinal conditions. Referable eyes for DR were 11.84%, with an additional 13% for other conditions (diagnoses included various stages of DR, media opacity, nevus, drusen, enlarged cup-to-disc ratio, pigmentary changes, and other). Artificial intelligence performance for overall detection of referable cases (both DR and other conditions) was as follows: sensitivity 84.23% (95% confidence interval (CI), 82.63e85.84), specificity 80.79% (95% CI,79.05e82.53). When we assessed whether AI matched any clinical diagnosis, be it referable or not, sensitivity was 85.67% (95% CI, 84.12e87.22), specificity was 98.86 (95% CI, 98.39e99.33), and area under the curve was 0.92 (95% CI, 0.91e0.94).

Conclusion

The integration of a portable device, AI analysis, and synchronous medical validation has the potential to play a crucial role in preventing blindness from DR, especially in socially unequal scenarios.

Icon Button Request A QuoteRequest a Quote

Fechar

Ico Back

Later

Request a quote

Fill out the form below and we will contact you shortly.

    Ico Form Success

    Request a Quote

    Our team will contact you shortly.

    Close

    …complete suas informações

      By clicking the Complete button I allow Phelcom to contact me regarding the above request and I declare that I have read and accept the terms of Privacy Policy and Terms of Use.
      Ico Back

      Depois

      Ico Form Success

      Obrigado por completar suas informações

      FECHAR

      Ico Back

      Depois

      Solicite e comece SEU TEST DRIVE

      Por favor, preencha o formulário abaixo que entraremos em contato.

        x

        Solicitar Orçamento

        Ao clicar em Solicitar, concordo com a Política de Privacidade e os Termos de Uso, permito que a Phelcom me contate e reconheço que o Eyer é um dispositivo médico (Anvisa classe II) exigindo a supervisão de um profissional com CRM para uso e interpretação das imagens.
        Ico Form Success

        Obrigado!

        Nosso time comercial logo entrará em contato para finalizar o processo.

        FECHAR

        Ico Back

        Later

        Request more information

        Please fill out the form below and we will contact you.

          x

          Request EyerMaps

          By clicking the Request button I allow Phelcom to contact me regarding the above request and I declare that I have read and accept the terms of Privacy Policy and Terms of Use.
          Ico Form Success

          Thank you!

          Our commercial team will contact you shortly to finalize the process.Our commercial team will contact you shortly to finalize the process.
          CLOSE